Erez Marcusohn

Erez Marcusohn

Auto-generated profile, based on publicly available information

Erez Marcusohn

Cardiology Department, Rambam Health Care Campus, Haifa, Israel

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
DEDanny Epstein
Danny Epstein
NPNeta Petersiel
Neta Petersiel
EKErez Klein
Erez Klein
EMErez Marcusohn
Erez Marcusohn
EAEyal Aviran
Eyal Aviran
LFLior Fuchs
Lior Fuchs

17 March 2023 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
SBShany Biton
Shany Biton
MAMohsin Aldhafeeri
Mohsin Aldhafeeri
EMErez Marcusohn
Erez Marcusohn
KTKenta Tsutsui
Kenta Tsutsui
TSTom SZWAGIER
Tom SZWAGIER
JBJoachim A. Behar
Joachim A. Behar
To drive health innovation that meets the needs of all and democratize healthcare, there is a need to assess the generalization performance of deep learning (DL) algorithms across various distribution shifts to ensure that these algorithms are robust. This retrospective study is, to the best of our knowledge, an original attempt to develop and assess the generalization performance of a DL model for AF events detection from long term beat-to-beat intervals across geography, ages and sexes. The new recurrent DL model, denoted ArNet2, is developed on a large retrospective dataset of 2,147 patients totaling 51,386 h obtained from continuous electrocardiogram (ECG). The model’s generalization is evaluated on manually annotated test sets from four centers (USA, Israel, Japan and China) totaling 402 patients. The model is further validated on a retrospective dataset of 1,825 consecutives Holter recordings from Israel. The model outperforms benchmark state-of-the-art models and generalized well across geography, ages and sexes. For the task of event detection ArNet2 performance was higher for female than male, higher for young adults (less than 61 years old) than other age groups and across geography. Finally, ArNet2 shows better performance for the test sets from the USA and China. The main finding explaining these variations is an impairment in performance in groups with a higher prevalence of atrial flutter (AFL). Our findings on the relative performance of ArNet2 across groups may have clinical implications on the choice of the preferred AF examination method to use relative to the group of interest.

1 May 2021 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
DEDanny Epstein
Danny Epstein
NSNeta Solomon
Neta Solomon
AKAlexander Korytny
Alexander Korytny
EMErez Marcusohn
Erez Marcusohn
YFYaacov Freund
Yaacov Freund
AMAsaf Miller
Asaf Miller

1 September 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
EMErez Marcusohn
Erez Marcusohn
MPMaria Postnikov
Maria Postnikov
AMAnees Musallam
Anees Musallam
SYSergey Yalonetsky
Sergey Yalonetsky
SMSnehil Mishra
Snehil Mishra
ARAriel Roguin
Ariel Roguin

22 November 2021 in Cardiac Failure Review
Verified
Journal Article
Open access
EMErez Marcusohn
Erez Marcusohn
Ofer KoboOfer Kobo
Ofer Kobo
MPMaria Postnikov
Maria Postnikov
DEDanny Epstein
Danny Epstein
YAYoram Agmon
Yoram Agmon
RZRobert Zukermann
Robert Zukermann
Background: Diagnosis of AF-induced cardiomyopathy can be challenging and relies on ruling out other causes of cardiomyopathy and, after restoration of sinus rhythm, recovery of left ventricular (LV) function. The aim of this study was to identify clinical and echocardiographic predictors for developing cardiomyopathy with systolic dysfunction in patients with atrial tachyarrhythmia. Methods: This retrospective study was conducted in a large tertiary care centre and compared patients who experienced deterioration of LV ejection fraction (EF) during paroxysmal AF, demonstrated by precardioversion transoesophageal echocardiography with patients with preserved LV function during AF. All patients had documented preserved LVEF at baseline (EF >50%) while in sinus rhythm. Results: Of 482 patients included in the final analysis, 80 (17%) had reduced and 402 (83%) had preserved LV function during the precardioversion transoesophageal echocardiography. Patients with reduced LVEF were more likely to be men and to have a more rapid ventricular response during AF or atrial flutter (AFL). A history of prosthetic valves was also identified as a risk factor for reduced LVEF. Patients with reduced LVEF also had higher incidence of tricuspid regurgitation and right ventricular dysfunction. Conclusion: In ‘real-world’ experience, male patients with rapid ventricular response during paroxysmal AF or AFL are more prone to LVEF reduction. Patients with prosthetic valves are also at risk for LVEF reduction during AF/AFL. Finally, tricuspid regurgitation and right ventricular dysfunction may indicate relatively long-standing AF with an associated reduction in LVEF.

1 August 2022 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
EMErez Marcusohn
Erez Marcusohn
IBItay Borreda
Itay Borreda
YHYaron Hellman
Yaron Hellman
MHManhal Habib
Manhal Habib
FBFadel Bahouth
Fadel Bahouth
RZRobert Zukermann
Robert Zukermann
Patients with heart failure (HF) with iron deficiency (ID) have worse New York Heart Association class and are at a higher risk of recurrent hospitalizations. Intravenous (IV) iron has been shown to improve exercise ability and reduce hospitalizations. IV sodium ferric gluconate complex (SFGC) has been found to be safe and affordable but has not been studied in this population in a randomized trial. This was a prospective, single-blind, investigator-initiated, randomized controlled trial. Patients admitted for acute heart failure with ID were randomly assigned 1:1 to receive IV SFGC on top of optimal medical treatment. The primary outcome was the change in the 6-minute walk test (6MWT) from baseline to 3 and 6 months. Between September 2019 and May 2021, 34 patients were randomized. 19 patients (55%) were randomized to the treatment arm receiving 125 mg of IV SFGC per day for 3–5 days. COVID-19 was a major barrier to the implementation of the study follow-up protocol, which caused the study to end early. Both groups of patients had similar clinical characteristics, comorbidities, median left ventricular ejection fraction, and rate of death and readmissions due to HF. A higher level of NT-proBNP was observed in patients treated with IV iron (7902 pg/mL vs. 3158, P = 0.04). There was no difference in 6MWT change between groups at 3 months (improvement of 21.6 vs. 24.1 meters) or 6 months (−5 meters vs. 46 meters). In conclusion, IV SFGC–treated patients had a comparable 6-minute walk at 3 and 6 months despite suffering from more severe HF with higher baseline NT-proBNP (NCT04063033).